model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Gemini-3-Pro,protocolSection.identificationModule.nctId,TP,TP,NCT02427958,NCT02427958,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.briefTitle,FN,FN,A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants,,False,0.0,,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,False,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.officialTitle,TP,TP,"An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty","An open label, multicenter clinical trial that investigated the efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children",True,0.97,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.briefSummary,TP,TP,The purpose of this study is to assess long-term safety and efficacy of leuprorelin in the treatment of Central Precocious Puberty (CPP).,"This prospective, open-label, multicenter clinical trial aimed to establish the long-term efficacy and safety of leuprorelin for the treatment of central precocious puberty (CPP) in children. Patients were treated with subcutaneous leuprorelin (1.88 to 3.75 mg) once every 4 weeks for a total of 96 weeks. The primary focus was on the rate of adverse events, while secondary objectives included monitoring the progression of puberty via Tanner staging, hormone concentrations, and bone age.",True,0.92,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.detailedDescription,TP,TP,"The drug in this study is called leuprorelin. It is administered as a 1 month subcutaneous depot injection. Leuprorelin is used to treat children who have CPP. This study will look at whether leuprorelin can stop early puberty in pre-pubertal children.

The study will enroll approximately 300 participants. Participants with body weight \>=20 kg will receive the recommended dose of leuprorelin 3.75 mg subcutaneous injection every 4 weeks for 96 weeks. Participants with body weight \<20 kg will receive recommended dose of 1.88 mg subcutaneous injection every 4 weeks for 96 weeks.

This trial will be conducted in China. The overall time to participate in this study is 104 weeks. Participants will make 11 visits to the clinic, and will be followed-up by the physician on a long-term basis until stable puberty is reached.","Leuprorelin is a gonadotropin-releasing hormone (GnRH) analog used to downregulate GnRH receptors and inhibit gonadotropin secretion, thereby preventing the development of secondary sexual characteristics in Central Precocious Puberty (CPP). While widely used, specific long-term safety and efficacy data for leuprorelin at doses of 30 to 180 μg/kg in the Chinese population were lacking.

This trial enrolled 307 children diagnosed with CPP across 11 medical centers in China between 2015 and 2018. The study design included a 4-week screening period, a 96-week treatment phase, and a 4-week safety follow-up. Eligible patients with a body mass ≥20 kg received 3.75 mg of leuprorelin subcutaneously every 4 weeks, while those with a body mass <20 kg received 1.88 mg. Dosage adjustments were permitted based on patient condition and investigator judgment.

The primary endpoint was the rate of occurrence of treatment-emergent adverse events (TEAEs). The main secondary endpoint was the percentage of patients experiencing regression or no progression in Tanner stage at week 96 compared to baseline. Additional efficacy endpoints included the suppression of peak Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) concentrations in stimulation tests, suppression of basal estradiol or testosterone concentrations, improvement in predicted adult height, changes in the ratio of bone age to chronological age, and changes in Body Mass Index (BMI) and Bone Mineral Density (BMD).",True,0.86,success,DetailedDescription,protocolSection.descriptionModule.detailedDescription,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.conditions,TP,TP,['Central Precocious Puberty'],['Central Precocious Puberty'],True,1.0,exact,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.keywords,TP,FP,['Drug Therapy'],"['Leuprorelin', 'GnRH analog', 'Children', 'Tanner stage', 'Puberty', 'Safety', 'Efficacy']",False,0.0,disjoint,Keyword,protocolSection.conditionsModule.keywords,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.phases,FN,FN,['PHASE4'],,False,0.0,,Phase,protocolSection.designModule.phases,False,True,False,False,False,False
Gemini-3-Pro,protocolSection.designModule.designInfo.allocation,TP,TP,NA,NA,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.interventionModel,TP,TP,SINGLE_GROUP,SINGLE_GROUP,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.interventionModelDescription,EV,EV,,Eligible CPP patients whose body mass was ≥20 kg received a leuprorelin dose of 3.75 mg subcutaneously once every 4 weeks. Eligible CPP patients with body mass <20 kg received a leuprorelin dose of 1.88 mg subcutaneously at 4-week intervals.,,,,DesignInterventionModelDescription,protocolSection.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,NONE,NONE,True,1.0,exact,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,Open label,,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.enrollmentInfo.count,TP,TP,307,307,True,1.0,exact,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.primaryOutcomes[0].description,EV,EV,,The primary safety endpoint was the rate of occurrence of adverse events (AEs) emerging during treatment. Safety assessment mainly involved monitoring of adverse events.,,,,PrimaryOutcomeDescription,protocolSection.outcomesModule.primaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[1].measure,EV,EV,,Percentage of patients with suppression of peak LH and FSH to pre-pubertal concentrations,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[2].measure,EV,EV,,Percentage of patients with suppression of basal E2 or testosterone concentrations to pre-pubertal concentrations,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[3].measure,EV,EV,,Percentage of patients with improvement in predicted adult height,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[4].measure,EV,EV,,Percentage of patients with a decrease in the ratio of Bone Age (BA) to Chronological Age (CA),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[5].measure,EV,EV,,Change in Body Mass Index (BMI),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[6].measure,EV,EV,,Change in Bone Mineral Density (BMD),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[1].description,EV,EV,,Assessed via GnRH stimulation test. Suppression defined as peak value ≤ Upper Limit Value (ULV). ULV for LH was 2 U/L (or >3.3 IU/L criteria mentioned in inclusion) and for FSH 6.7 U/L.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[2].description,EV,EV,,Suppression of basal Estradiol (E2) in female patients (ULV 20 pg/mL) or testosterone concentrations in male patients.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[3].description,EV,EV,,Predicted adult height was evaluated using the Bayley–Pinneau method.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[4].description,EV,EV,,Bone age was evaluated using Tanner-Whitehouse 3 standards.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[5].description,EV,EV,,Change in BMI values.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[6].description,EV,EV,,Change in BMD values.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[1].timeFrame,EV,EV,,Week 96,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[2].timeFrame,EV,EV,,Week 96,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[3].timeFrame,EV,EV,,Week 96 compared to baseline,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[4].timeFrame,EV,EV,,Week 96 compared to baseline,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[5].timeFrame,EV,EV,,Baseline to Week 96,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[6].timeFrame,EV,EV,,Baseline to Week 96,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion Criteria:

1. In the opinion of the investigator, the participant and/or parent(s) or legal guardian are capable of understanding and complying with protocol requirements.
2. The participant or the participant's parent(s) or legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
3. Has onset of appearance of secondary sexual characteristic earlier than age 8.0 years in girls or earlier than 9.0 years in boys and the symptom is persistent, and has confirmed diagnosis of CPP.
4. Has basal luteinizing hormone (LH) level greater than (\>) 5.0 international units per liter (IU/L) or peak LH \>3.3 IU/L with LH/follicle-stimulating factor (FSH) \>0.6 in stimulation test.
5. Has evidence of gonadal development evaluated by ultrasonography: ovarian volume \>=1 milliliter (mL) with multiple follicles \>=4 millimeter (mm) in any ovary or uterine enlargement in females or testicular volume \>=4 mL in males.
6. Has advanced bone age (BA) \>=1 year and BA is less than or equal to (\<=) 11.5 years in females or \<=12.5 years in males OR predicted adult height \<150 centimeter (cm) in females or \<160 cm in males OR standard deviation score (SDS) \<-2 standard deviations (SD) OR rapid growth defined as growth of BA /growth of chronologic age \>1. BA is determined by Greulich and Pyle standards or Tanner-Whitehouse 3 (TW3) standards at screening.
7. Has anticipated treatment duration of at least 2 year in investigator's judgment.
8. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 90 days after last dose.
9. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.
10. The female participant who, at the discretion of the investigator, is deemed to be of child bearing potential must provide negative urine pregnancy text at Day -1 or Day 1 prior to drug administration.

Exclusion Criteria:

1. Has received any investigational compound within 30 days prior to Screening.
2. Has received gonadotropin-releasing hormone analog (GnRHa) treatment in a previous clinical study or as a therapeutic agent.
3. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (example \[eg\], spouse, parent, child, sibling) or may consent under duress.
4. Has any findings in his/her medical history, physical examination, or safety clinical laboratory tests giving reasonable suspicion of underlying disease that might interfere with the conduct of the trial.
5. Has any concomitant medical condition that, in the opinion of the investigator, may expose a participant to an unacceptable level of safety risk or that affects participant compliance.
6. Has any screening abnormal laboratory value that suggests a clinically significant underlying disease or condition that may prevent the participant from entering the study; or the participant has: creatinine \>=1.5 milligram per deciliter (mg/dL), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>2 times the upper limit of normal (ULN), or total bilirubin \>2.0 mg/dL, with AST/ALT elevated above the limits of normal values.
7. Has a history or clinical manifestations of significant adrenal or thyroid diseases or intracranial tumor OR has a history of malignant disease.
8. Has a history of hypersensitivity or allergies to leuprorelin, or related compounds including any excipients of the compound.
9. Has a diagnosis of peripheral precocious puberty.
10. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening Visit.
11. Participant or parent(s), at the discretion of the investigator, is unlikely to comply with the protocol or is unsuitable for any of other reason.
12. If female, the participant is of childbearing potential (eg, not sterilized).
13. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
14. If male, the participant intends to donate sperm during the course of this study or for 90 days thereafter.
15. Has participated in another clinical study and/or has received any investigational compound within 30 days prior to Screening.","Inclusion Criteria:
* Secondary sexual characteristics appearance at age <8 years in girls or <9 years in boys, with persistent symptoms
* CPP diagnosis confirmed
* A basal concentration of LH >5.0 IU/L or a peak LH concentration >3.3 IU/L and LH/FSH >0.6 IU/L in the stimulation test
* Ultrasonographic evidence of gonadal development
* Advanced BA for ≥1 year with BA ≤11.5 years in females and ≤12.5 years in males
* Predicted adult females height <150 or <160 cm for males; and SDS <−2SD; or rapid growth of the BA/chronologic age >1

Exclusion Criteria:
* A patient had been given an experimental drug up to 30 days prior to potential enrollment
* The patient had been treated with GnRHa in a previous trial
* Had abnormal laboratory values suggesting an underlying ailment or creatinine ≥1.5 mg/dL
* Alanine aminotransferase and/or aspartate aminotransferase >twice the normal higher limits
* Total bilirubin concentration >2.0 mg/dL, with aspartate aminotransferase/alanine aminotransferase elevated above normal levels
* Clinical signs or a previous history of kidney or thyroid disease
* Diagnosed with peripheral precocious puberty
* A history of hypersensitivity or allergies to leuprorelin or related compounds including any excipients of the compound
* A history or clinical manifestations of significant adrenal or thyroid diseases or intracranial tumor
* Had a history of malignant disease",True,0.9,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.eligibilityModule.minimumAge,TP,FP,1 Year,N/A,False,0.1,success,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.maximumAge,TP,FP,9 Years,N/A,False,0.05,success,MaximumAge,protocolSection.eligibilityModule.maximumAge,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.stdAges,TP,TP,['CHILD'],['CHILD'],True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
